Status:
COMPLETED
A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
Bristol-Myers Squibb
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
The purpose of this clinical research study is to assess the safety of, exposure to, and biological effects of BMS-512148 in stable Type 2 diabetic subjects
Eligibility Criteria
Inclusion
- Established diagnosis of Type 2 diabetes mellitus, who are treated with metformin or diet alone (drug naive).
- Fasting glucose (FG) \< - 240 mg/dL, while on metformin or antidiabetic diet alone.
- HbA1c (Hemoglobin A1c) in the range of 6.0-10.0%
Exclusion
- Women of childbearing potential
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2005
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT00162305
Start Date
April 1 2005
End Date
August 1 2005
Last Update
October 27 2016
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Fort Lauderdale, Florida, United States, 33301
2
Local Institution
Miami, Florida, United States, 33169
3
Local Institution
Orlando, Florida, United States, 32809
4
Local Institution
New Orleans, Louisiana, United States, 70119